Direxion Daily CSI China Internet Bull 2X Shares vs Revvity Inc — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $18.19 (market cap $173.62M), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 97.8× Direxion Daily CSI China Internet Bull 2X Shares's market cap, and Revvity Inc pays a 0.18% dividend while Direxion Daily CSI China Internet Bull 2X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily CSI China Internet Bull 2X Shares for 24 Days and Revvity Inc for 12 Days on average.
| CWEB | RVTY | |
|---|---|---|
Market Cap | $173.62M | $16.98B |
Volume | 551,726 | 1,456,900 |
Sector | Leveraged / Inverse | Health |
52-Week High | $55.62 | $157.36 |
52-Week Low | $17.39 | $82.26 |
Typical Hold Time | 24 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
CWEB trades at $18.02, down 1.85% today amid bearish technical signals. The stock shows weak momentum with all 13 moving averages signaling sell, though oscillators are neutral. Recent news highlights China's AI ambitions and potential for China growth stocks to surge, providing thematic catalysts. Financial ratios remain undisclosed in current data.
Outlook hinges on China's tech sector recovery and AI growth narrative. Risks include geopolitical tensions and market volatility. The upcoming dividend of $0.07 in September 2026 offers income potential, but investors need clarity on fundamentals for sustained upside.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28. The stock shows bullish technical momentum with consistent earnings beats in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. Operating cash flow improved to $628 million in 2026 from $583 million in 2025.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics pose near-term risks. The company faces margin pressures in China and competitive challenges. With 52% analyst buy ratings and strong institutional interest, the stock offers upside to the $165 high target but requires monitoring of Q3 earnings due November 3.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →